Quartz 4

Research: Update Existing Regulatory Concepts

6 min read

Research: Update Existing Regulatory Concepts

FTC Substantiation Guidelines and Competent and Reliable Scientific Evidence

The regulatory landscape governing health and wellness advertising is heavily scrutinized by the ftc and the fda. Enforcement risk is currently at a peak for functional foods, dietary supplements, and brands utilizing adaptogens, where influencer content and lifestyle marketing often blur the line into implied health or efficacy claims [1]. To mitigate consumer deception, the FTC requires that all objective health and wellness claims be substantiated by competent-and-reliable-scientific-evidence (CRSE) [1, 2].

Defining Competent and Reliable Scientific Evidence (CRSE)

Under FTC regulations, advertisers must possess a reasonable basis for their claims before they are disseminated. For health, safety, performance, or efficacy representations, this reasonable basis is defined as competent-and-reliable-scientific-evidence [2].

The FTC defines CRSE as tests, analyses, research, or studies that:

  1. Have been conducted and evaluated in an objective manner by experts qualified in the relevant disease, condition, or function [2, 5].
  2. Utilize procedures generally accepted in the profession to yield accurate and reliable results [3, 5].
  3. Are sufficient in quality and quantity when evaluated in light of the entire body of relevant and reliable scientific evidence [2, 5].

This standard dictates that companies cannot cherry-pick favorable studies while ignoring a broader consensus of contradictory research [7].

The Gold Standard: Randomized Controlled Trials (RCTs)

While the FTC has historically described CRSE as a “flexible” standard with no fixed formula for the number or type of required studies [3], recent updates to the FTC’s Health Products Compliance Guidance have formalized stricter expectations. Today, substantiating health-related benefits generally requires randomized, controlled human clinical trials (RCTs) [5, 7].

Essential Principles of Valid Research

To satisfy the FTC, studies must adhere to basic principles of valid scientific research, including:

  • Control Groups and Randomization: Trials must feature a treatment and a control group, utilizing randomization or careful matching criteria [7, 9].
  • Blinding: Double-blind studies are highly preferred to eliminate placebo effects and researcher bias [6, 7].
  • Peer Review and IRB Approval: Protocols should be clear, detailed, and ideally submitted to an Institutional Review Board (IRB) following Good Clinical Practice (GCP) [7, 8].

The FTC generally does not consider epidemiological or observational studies, animal and in vitro studies, public health recommendations, or consumer anecdotes to be sufficient CRSE on their own [7]. Relying on multiple flawed studies does not equate to relying on one scientifically sound study [7].

Statistical Significance vs. Clinical Meaningfulness

A critical requirement of CRSE is that research findings must be both statistically significant and clinically meaningful [6, 7, 9].

  • Statistical Significance: Measured by a p-value (e.g., p<0.05), indicating that the results are unlikely to have occurred by random chance [8].
  • Clinical Meaningfulness: A study may achieve statistical significance due to a massive sample size, but the actual health benefit could be trivial. The FTC requires that the measured effects translate into a tangible, meaningful benefit for consumer health [6, 8].

Regulatory Flexibility, “Borrowed Science,” and Essential Equivalence

Addressing the clinical-substantiation-gap, brands often rely on existing scientific literature rather than funding proprietary RCTs. The FTC permits this practice—sometimes called “borrowed science”—if the product being marketed is “essentially equivalent” to the product tested in the literature [4].

A product is considered essentially equivalent if it contains identical active ingredients in the same form, dosage, and route of administration [4]. If a brand adds additional ingredients, it must possess reliable scientific evidence demonstrating that the new formulation does not impede or inhibit the effectiveness of the primary active ingredients [4]. The FTC does not strictly require clinical studies to be published in peer-reviewed journals to be relied upon, which protects brands from having their formulas easily copied by competitors lacking patent protections [3].

Enforcement Precedents: The Tightening of Standards

The boundaries of functional-beverage-regulations and health claims are often defined through consent decrees and litigation.

A landmark case is the 2010 FTC consent decree with Nestle regarding Boost® Kid Essentials [4]. The FTC alleged that Nestle made unsubstantiated claims regarding the prevention of upper respiratory tract infections and the reduction of school absences due to illness. The resulting order imposed a strict two-well-controlled-clinical-trials minimum for specific disease-related claims, elevating the burden of proof above the traditional, single-study CRSE baseline [4]. However, traditional CRSE was maintained for broader, less specific efficacy claims [4]. This case underscores the tension between permissible structure-function-vs-drug-claims and the FTC’s willingness to escalate substantiation requirements when public health (especially children’s health) is involved.

Furthermore, utilizing mechanisms like notices-of-penalty-offenses, the FTC can impose severe civil penalties on brands that ignore established substantiation guidelines, exacerbating the risks for brands operating in the beverage-vs-supplement-ambiguity space.

Contradictions and Gaps in the Research

  • The Single-Study Paradox: There is a slight contradiction in the FTC’s posturing. Court cases like Brain Research Labs, LLC v. FTC affirmed that CRSE is a “flexible” standard where a single study may suffice [3]. However, newer FTC guidance heavily stresses that independent replication is vital because it reduces the chance of systematic biases [5]. While one flawless RCT might legally suffice, the FTC clearly penalizes brands that lack secondary verification for bold claims.
  • Dosage Realities vs. Beverage Economics: The research highlights the necessity of matching test dosages to retail dosages [4]. A significant gap exists in how beverage manufacturers can affordably dose adaptogens at clinical levels without ruining the taste profile or exceeding standard Cost of Goods Sold (COGS).
  • Warning Letters Analysis: Search for joint FDA/FTC warning letters specifically targeting CBD or adaptogen-infused beverages to observe real-world applications of the CRSE standard.
  • Litigation on “Puffery” vs. Health Claims: Investigate recent case law defining where subjective wellness marketing (e.g., “find your center” or “elevate your mood”) crosses the threshold into an objective health claim requiring CRSE.
  • International Standards: Compare the FTC’s CRSE with the European Food Safety Authority’s (EFSA) rigorous clinical evidence requirements to broaden the global perspective on functional-beverage-regulations.

References

  1. [PDF] food-beverage-and-consumer-products-issues-to-watch-for-2026.pdf — armstrongteasdale.com
  2. [PDF] Health Research: Decision and Order - Federal Trade Commission — ftc.gov
  3. Understanding FTC Standards for Claims Substantiation - Nutraceuticals World — nutraceuticalsworld.com
  4. The FTC’s “Beefed Up” Definition Of Competent And Reliable Scientific Evidence And POM’s Counter-Offensive — ccbjournal.com
  5. Health Products Compliance Guidance - Federal Trade Commission — ftc.gov
  6. [PDF] Dietary Supplements: An Advertising Guide for Industry — ftc.gov
  7. [PDF] FTC Releases Health Products Compliance Guidance — wsgr.com
  8. [PDF] Dietary Supplement Claims Substantiation E-Book: - HubSpot — cdn2.hubspot.net
  9. [PDF] FTC Revises and Expands Guidance for Health Claims - Kslaw.com — kslaw.com

Graph View